Molecular Response After 3 Months of 1st Line Imatinib Therapy Is Predictive for Treatment Failure and Disease Progression In Patients with Chronic Phase Chronic Myeloid Leukemia - a Follow-up Analysis of the German CML Study IV

被引：0
|
作者：
Hanfstein, Benjamin [1 ]
Mueller, Martin C. [1 ]
Erben, Philipp [1 ]
Schnittger, Susanne [2 ]
Saussele, Susanne [1 ]
Leitner, Armin [1 ]
Proetel, Ulrike [1 ]
Ehninger, Gerhard [3 ]
Hossfeld, Dieter K.
Kolb, Hans-Jochem [4 ,7 ]
Krause, Stefan W. [5 ]
Nerl, Christoph [6 ]
Pralle, Hans
Heim, Dominik [8 ]
Baerlocher, Gabriela M.
Heimpel, Hermann [9 ]
Hehlmann, Ruediger [1 ]
Hochhaus, Andreas [10 ]
机构：
[1] Univ Heidelberg, Med Fak Mannheim, Med Klin 3, D-6800 Mannheim, Germany
[2] MLL, Munich, Germany
[3] Univ Klinikum Carl Gustav Carus Dresden, Med Klin & Poliklin 1, Dresden, Germany
[4] Klinikum Univ Munchen Grosshadern, Med Klin & Poliklin 3, Munich, Germany
[5] Univ Klinikum Erlangen, Med Klin 5, Erlangen, Germany
[6] Krankenhaus Munchen Schwabing, Munich, Germany
[7] Univ Giessen, Giessen, Germany
[8] Univ Spital Basel, Dept Hematol, Basel, Switzerland
[9] Univ Ulm Klinikum, Innere Med Klin 3, Ulm, Germany
[10] Univ Klinikum Jena, Innere Med Klin 3, Jena, Germany
来源：
BLOOD | 2010年 / 116卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：162 / 163
页数：2
相关论文
共 50 条
  • [21] Molecular responses of late chronic phase chronic myeloid leukemia patients after achieving complete cytogenetic responses with imatinib treatment: a 6-year follow-up
    YaZhen Qin
    Bin Jiang
    Qian Jiang
    Hao Jiang
    JinLan Li
    Yan Zhang
    HongHu Zhu
    LingDi Li
    ShanShan Chen
    YanRong Liu
    XiaoJun Huang
    Annals of Hematology, 2009, 88 : 37 - 41
  • [22] Long-Term Follow-up of a Phase 1 Study of Ponatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML)
    Talpaz, Moshe
    Cortes, Jorge E.
    Kantarjian, Hagop
    Shah, Neil P.
    Bixby, Dale
    Flinn, Ian
    O'Hare, Thomas
    Hu, Simin
    Rivera, Victor M.
    Clackson, Tim
    Turner, Christopher D.
    Haluska, Frank G.
    Druker, Brian J.
    Deininger, Michael W.
    Mauro, Michael J.
    BLOOD, 2014, 124 (21)
  • [23] NILOTINIB IN CHRONIC MYELOID LEUKEMIA PATIENTS IN CHRONIC PHASE (CML-CP) WITH IMATINIB RESISTANCE OR INTOLERANCE: 24-MONTH FOLLOW-UP RESULTS OF A PHASE 2 STUDY
    Kantarjian, H.
    Giles, F. G.
    Bhalla, K. N. P.
    Pinilla, J.
    Larson, R. A.
    Gattermann, N.
    Ottmann, O. G.
    Wang, J.
    Gallagher, N. J.
    Baccarani, M.
    Le Coutre, P. D.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 254 - 255
  • [24] Nilotinib in Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) with Imatinib Resistance or Intolerance: 2-Year Follow-up Results of a Phase 2 Study
    Kantarjian, Hagop M.
    Giles, Francis
    Bhalla, Kapil N.
    Larson, Richard A.
    Gattermann, Norbert
    Ottmann, Oliver G.
    Haque, Ariful
    Gallagher, Neil J.
    Baccarani, Michele
    le Coutre, Philipp D.
    BLOOD, 2008, 112 (11) : 1112 - 1112
  • [25] Molecular Response at 3 Months On Nilotinib Therapy Predicts Response and Long-Term Outcomes in Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
    Branford, Susan
    Kim, Dong-Wook
    Soverini, Simona
    Gottardi, Enrico
    Beppu, Lan
    Mueller, Martin C.
    Haque, Ariful
    Shou, Yaping
    Woodman, Richard C.
    Kantarjian, Hagop M.
    Martinelli, Giovanni
    Radich, Jerald P.
    Saglio, Giuseppe
    Hughes, Timothy P.
    Hochhaus, Andreas
    BLOOD, 2009, 114 (22) : 1275 - 1276
  • [26] Complete cytogenetic response after 12 months of treatment and within 1 year of imatinib therapy in patients with late chronic phase chronic myeloid leukemia Ph+
    Klamova, H.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 531 - 531
  • [27] No Differences in Outcomes Between Patients Achieving Early Molecular Response at 3 Months and Those Achieving Optimal Response at 6 or 12 Months in Chronic Phase of Chronic Myeloid Leukemia Treated with Front-Line Imatinib: Taiwan CML Study
    Kuo, Ming-Chung
    Chen, Tsai-Yun
    Wang, Ming-Chung
    Yang, Youngsen
    Yeh, Su-Peng
    Chang, Cheng-Shyong
    Lan, Yii-Jenq
    Chen, Chih-Cheng
    Su, Yu-Chieh
    Hsiao, Pei-Ching
    Kuo, Ching-Yuan
    Bai, Li-Yuan
    Hwang, Wen-Li
    Shih, Lee-Yung
    BLOOD, 2014, 124 (21)
  • [28] Long-term follow-up of late chronic phase chronic myeloid leukemia patients treated with imatinib after interferon failure: a single center experience
    Pepe, Sara
    Scalzulli, Emilia
    Colafigli, Gioia
    Di Prima, Alessio
    Mancini, Marco
    Diverio, Daniela
    Latagliata, Roberto
    Martelli, Maurizio
    Foa, Robin
    Breccia, Massimo
    LEUKEMIA & LYMPHOMA, 2021, 62 (09) : 2261 - 2266
  • [29] The Efficacy of Generic Imatinib as First- and Second-line Therapy: 3-Year Follow-up of Patients With Chronic Myeloid Leukemia
    Islamagic, Erna
    Hasic, Azra
    Kurtovic, Sabira
    Hadzimesic, Emina Suljovic
    Mehinovic, Lejla
    Kozaric, Mirza
    Kurtovic-Kozaric, Amina
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (04): : 238 - 240
  • [30] Long-Term Follow-up after Treatment Discontinuation in Patients with Chronic Myeloid Leukemia: The Korean Imatinib Discontinuation (KID) Study
    Zang, Dae Young
    Lee, Won Sik
    Mun, Yeung-Chul
    Do, Young Rok
    Oh, Sukjoong
    Lee, Sung-Eun
    Choi, Soo Young
    Kim, Dong-Wook
    BLOOD, 2018, 132
12345